Literature DB >> 10030273

Computerized design of target margins for treatment uncertainties in conformal radiotherapy.

G S Mageras1, Z Fuks, S A Leibel, C C Ling, M J Zelefsky, H M Kooy, M van Herk, G J Kutcher.   

Abstract

PURPOSE: We describe a computerized method of determining target margins for beam aperture design in conformal radiotherapy plans.
MATERIALS AND METHODS: The method uses previously measured data from a population of patients to simulate setup error and organ motion in the patient currently being planned. Starting with a clinical target volume (CTV) and nontarget organs from the patient's planning CT scan, the simulation is repeated many times to produce a spatial probability distribution for each organ in the treatment machine coordinate system. This is used to determine a prescribed dose volume (PDV), defined as the volume to receive the prescribed dose, which encompasses the CTV while restricting the volume of nontarget organs within it, according to planner-specified values. The PDV is used to design beam apertures using a conventional margin for beam penumbra.
RESULTS: The method is applied to 6-field prostate conformal treatment plans, in which the PDV encloses the prostate and seminal vesicles while limiting the enclosed rectal wall volume. The effect of organ motion is assessed by applying the plans on subsequent CT scans of the same patients, calculating probabilities for tumor control (TCP) and normal tissue complication (NTCP), and comparing with plans designed from a physician-drawn planning target volume (PTV). Although prostate TCP and rectal wall NTCP are found to be similar in the two sets of plans, TCP for the seminal vesicles is significantly higher in the PDV-based plans.
CONCLUSIONS: The method can improve the dose conformality of treatment plans by incorporating population-based measurements of treatment uncertainties and consideration of nontarget tissues in the design of nonuniform target margins.

Entities:  

Mesh:

Year:  1999        PMID: 10030273     DOI: 10.1016/s0360-3016(98)00386-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Practical approaches to four-dimensional heavy-charged-particle lung therapy.

Authors:  Shinichiro Mori; Ziji Wu; Michael R Folkert; Motoki Kumagai; Suguru Dobashi; Toshio Sugane; Masayuki Baba
Journal:  Radiol Phys Technol       Date:  2009-10-14

2.  Correction of systematic set-up error in breast and head and neck irradiation through a no-action level (NAL) protocol.

Authors:  Eva M Lozano; Luis A Pérez; Javier Torres; Carmen Carrascosa; Miguel Sanz; Fermín Mendicote; Antonio Gil
Journal:  Clin Transl Oncol       Date:  2011-01       Impact factor: 3.405

3.  Reduction of prostate intrafractional motion from shortening the treatment time.

Authors:  Jin Sheng Li; Mu-Han Lin; Mark K Buyyounouski; Eric M Horwitz; Chang-Ming Ma
Journal:  Phys Med Biol       Date:  2013-06-25       Impact factor: 3.609

4.  Optimizing principal component models for representing interfraction variation in lung cancer radiotherapy.

Authors:  Ahmed M Badawi; Elisabeth Weiss; William C Sleeman; Chenyu Yan; Geoffrey D Hugo
Journal:  Med Phys       Date:  2010-09       Impact factor: 4.071

5.  How does performance of ultrasound tissue typing affect design of prostate IMRT dose-painting protocols?

Authors:  Pengpeng Zhang; K Sunshine Osterman; Tian Liu; Xiang Li; Jack Kessel; Leester Wu; Peter Schiff; Gerald J Kutcher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-01       Impact factor: 7.038

6.  The effects of the shape and size of the clinical target volume on the planning target volume margin.

Authors:  Buhong Zheng; Zhiyu Huang; Jinluan Li
Journal:  PLoS One       Date:  2014-10-02       Impact factor: 3.240

7.  The investigation on the location effect of external markers in respiratory-gated radiotherapy.

Authors:  Hui Yan; Guopei Zhu; James Yang; Mei Lu; Munther Ajlouni; Jae Ho Kim; Fang-Fang Yin
Journal:  J Appl Clin Med Phys       Date:  2008-04-16       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.